FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion
This article was originally published in The Pink Sheet Daily
The Office of Medical Policy now houses the Office of Prescription Drug Promotion (formerly DDMAC) and the newly created Office of Medical Policy Initiatives.
You may also be interested in...
Chief Scientist At US FDA Is Hinton As Borio Moves To White House
Luciana Borio is detailed to National Security Council; FDA promotes Denise Hinton to acting chief scientist.
FDA Policy In Biosimilars, “Breakthrough” And Social Media Under New Management
Office of Medical Policy’s leadership gets reshuffled following retirement of the long-time CDER denizen Rachel Sherman.
Generic Drugs Gain Status Boost Within CDER
More than just a bureaucratic shell game, the promotion of the Office of Generic Drugs to “super office” status signals CDER Director Janet Woodcock’s tightened focus on generic drugs.